COVAGEN
Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy. Their goal is to access novel biology for each product candidate. Covagenโs lead FynomAb COVA322 is being developed for the t... reatment of inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. In October 2012 Covagen entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe / TRL for the development of bispecific FynomAbs against target pairs selected by Mitsubishi Tanabe / TRL. Covagen was founded in 2007 as a spin-off company from ETH Zurich (Swiss Federal Institute of Technology). A strong syndicate of investors supports Covagenโs drug development programs including Novartis Venture Fund, Edmond de Rothschild Investment Partners, Gimv, Seroba Kernel Life Sciences, Ventech, Ascent Biomedical Venture Management, MP Healthcare Venture Management, and Baxter Ventures.
COVAGEN
Social Links:
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2007-01-01
Address:
Schlieren, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.covagen.com
Total Employee:
11+
Status:
Closed
Contact:
41 44 732 46 60
Total Funding:
106.63 M USD
Current Advisors List
Current Employees Featured
Founder
Investors List
Seroba Life Sciences
Seroba Life Sciences investment in Series B - Covagen
Baxter Ventures
Baxter Ventures investment in Series B - Covagen
Gimv
Gimv investment in Series B - Covagen
Ventech
Ventech investment in Series B - Covagen
Andera Partners
Andera Partners investment in Series B - Covagen
Novartis Venture Fund
Novartis Venture Fund investment in Series B - Covagen
MP Healthcare Venture Management
MP Healthcare Venture Management investment in Series B - Covagen
Ascent Biomedical Ventures
Ascent Biomedical Ventures investment in Series B - Covagen
Edmond de Rothschild Private Equity
Edmond de Rothschild Private Equity investment in Series B - Covagen
Ventech
Ventech investment in Series A - Covagen